Differential cutoff points and clinical impact of stent parameters of various drug-eluting stents for predicting major adverse clinical events: An individual patient data pooled analysis of seven stent-specific registries and 17,068 patients

• Published in: International journal of cardiology 2019-05, Vol.282, p.17-23
• Main Authors: Lee, Cheol Hyun, Kang, Do-Yoon, Han, Minkyu, Hur, Seung-Ho, Rha, Seung-Woon, Her, Sung-Ho, Seung, Ki-Bae, Kim, Kee-Sik, Lee, Pil-Hyung, Ahn, Jung-Min, Lee, Seung-Whan, Park, Seong-Wook, Park, Duk-Woo, Park, Seung-Jung
• Format: Article
• Language: English
• Subjects: Aged; Cardiovascular Diseases - diagnosis; Cardiovascular Diseases - etiology; Cardiovascular Diseases - therapy; Coronary artery disease; Data Analysis; Drug-eluting stents; Drug-Eluting Stents - adverse effects; Drug-Eluting Stents - standards; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous coronary intervention; Predictive Value of Tests; Prospective Studies; Registries - standards
• ISSN: 0167-5273; 1874-1754
• DOI: 10.1016/j.ijcard.2019.01.108

Stent parameters (length and diameter) are well-known risk factors for adverse outcomes after percutaneous coronary intervention (PCI) with stenting. This study aimed to investigate the differential cutoff criteria and clinical impact of the length and diameter of various drug-eluting stents (DES) for predicting major cardiovascular events. Using patient-level data from seven stent-specific, prospective DES registries, we evaluated 17,068 patients who underwent PCI with either various contemporary DES or first-generation DES between July 2007 and July 2015: 3053 treated with cobalt-chromium everolimus-eluting stents (CoCr-EES), 2976 with platinum-chromium EES (PtCr-EES), 2888 with Resolute zotarolimus-eluting stents (Re-ZES), 782 with Biomatrix biolimus-eluting stents (Bi-BES), 1868 with Nobori BES (No-BES), 1934 with Xience Prime cobalt-chromium EES (Pr-CoCr-EES), and 3567 with first-generation sirolimus-eluting stents (SES). Two clinical outcomes were assessed: target-vessel failure (TVF; a composite of cardiac death, target-vessel myocardial infarction, and target-vessel revascularization [TVR]) and TVR. Stent length and stent diameter were important factors for predicting TVF or TVR in the entire cohort and in each DES cohort. For TVF risk prediction, the Youden index-based cutoff of stent length was highest with Bi-BES (45.0 mm) and lowest with No-BES (29.0 mm), and the cutoff of stent diameter was smallest with Pr-CoCr-EES (2.78 mm) and largest with No-BES (3.20 mm). For TVR risk prediction, the cutoff of stent length was the highest with PtCr-EES (48.0 mm) and the lowest with No-BES (29.0 mm), and the cutoff of stent diameter was smallest with CoCr-EES (2.72 mm) and largest with first-generation SES (3.30 mm). The 3-year TVF and TVR rates were substantially different according to the presence or absence of long lesions and small vessels determined using these cutoff points. For contemporary PCI practice involving diverse types of DES, we identified differential cutoff points of stent length and diameter for predicting adverse clinical outcomes. The clinical impact of these stent parameters on outcomes and its magnitude varied according to different DES. Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT01186133.